ABVACC, INC.

ABVACC, INC. specializes in the research and development of novel therapeutic biologics, with a demonstrated focus on monoclonal antibody platforms for high-consequence viral pathogens. Their technical expertise centers on antibody discovery, characterization, and preclinical development of targeted immunotherapies, particularly in the context of emerging infectious disease threats such as Marburgvirus. The company applies rigorous structural and functional analysis to engineer high-affinity, neutralizing antibodies with optimized pharmacokinetic profiles, positioning them at the intersection of virology, immunology, and biotherapeutics development. Their work reflects deep competency in epitope mapping, in vitro neutralization assays, and preclinical candidate selection—core competencies critical to advancing next-generation biologics for biosurveillance and pandemic preparedness. The contractor has delivered research services exclusively to the Department of Health and Human Services, indicating a focused alignment with public health emergency response and biomedical innovation initiatives under agencies such as BARDA or NIAID. Their engagement reflects a trusted partnership in developing medical countermeasures for biothreat agents, suggesting a track record of meeting stringent federal biodefense and therapeutic development timelines and regulatory standards. ABVACC, INC. operates primarily under NAICS 541715, which encompasses applied scientific research in life sciences excluding biotechnology and nanotechnology—indicating a focus on classical molecular and cellular approaches to therapeutic development rather than platform-based biotech methods. This places them in a niche segment of the federal biomedical R&D market, where precision antibody engineering and pathogen-specific intervention strategies are prioritized. As a small business structured as a 2L entity based in Rockville, Maryland, ABVACC, INC. leverages its proximity to federal health research hubs and biodefense infrastructure. While currently holding no formal government certifications, its location and project focus suggest strategic alignment with the National Institutes of Health ecosystem and the broader U.S. biodefense research community.